Skip to main content

News

Consumers Can Now Buy a Blood Test to Evaluate Their Alzheimer Disease Risk, but Should They?

By Carousel Slider, In the News, UCI MIND

Consumers can order blood tests from the laboratory testing behemoth Quest Diagnostics to check their iron or vitamin D levels, learn whether they have a sexually transmitted disease, or determine whether their thyroid is functioning properly. And now, for $399, plus a $13 “physician service fee,” they can order a blood test that promises to help assess their risk of Alzheimer disease. In a press release, Quest Diagnostics noted that its AD-Detect Test for Alzheimer Disease is the first blood test available for consumers to purchase that measures a biomarker linked to the most common form of dementia. The test uses liquid…

The post Consumers Can Now Buy a Blood Test to Evaluate Their Alzheimer Disease Risk, but Should They? appeared first on UCI MIND.

Read More

Taking Medication For High Blood Pressure May Lower Your Dementia Risk

By Carousel Slider, In the News, UCI MIND

Treating high blood pressure in older adults reduces their risk of dementia, an analysis of previous research shows, providing more evidence that heart health and brain health are intimately connected. In a new meta-analysis, published Sept. 12 in JAMA Network Open, researchers found that older adults with untreated high blood pressure were 42% more likely to develop dementia during the study period compared to healthy older adults. This was true even among 70- and 80-year-olds. […] “The study suggests that successful treatment of hypertension [high blood pressure] might bring down the risk of developing dementia to the level of individuals with no hypertension,” said Dr. S….

The post Taking Medication For High Blood Pressure May Lower Your Dementia Risk appeared first on UCI MIND.

Read More

Celebrating 2023 Lauds & Laurels Honoree Andrea Wasserman

By Carousel Slider, In the News, UCI MIND

Dear Colleagues, I am thrilled to announce and celebrate four outstanding individuals who have been honored with Lauds & Laurels awards. These individuals have not only excelled in their respective fields but have also demonstrated exceptional dedication and a relentless pursuit of excellence. Dr. Tamera Hatfield, PhD, an alumna of our school, has been awarded the Distinguished Alumni award. Dr. Hatfield’s academic journey at the School of Biological Sciences and the UCI School of Medicine has culminated in her becoming a board-certified, fellowship-trained UCI Health obstetrician. Andrea Wasserman, the Chief Administrative Officer of the UC Irvine Institute for Memory Impairments…

The post Celebrating 2023 Lauds & Laurels Honoree Andrea Wasserman appeared first on UCI MIND.

Read More

Early-stage trial for Parkinson’s disease therapy shows signs of promise

By Carousel Slider, In the News, UCI MIND

Small trial of Bemdaneprocel, which aims to replace dopamine-producing neurons, raises hope for treatment Scientists have reported early success in a trial of an experimental cell therapy for Parkinson’s disease, raising hope for patients. Bemdaneprocel therapy is at an early stage, and the year-long trial involved just 12 patients, but the positive outcome is viewed as significant after decades of setbacks in the hunt for an effective treatment. Developed by BlueRock therapeutics, a subsidiary of the pharmaceutical company Bayer, it was shown to be safe and the data gave a tantalising suggestion that patients may have benefited. “The data from…

The post Early-stage trial for Parkinson’s disease therapy shows signs of promise appeared first on UCI MIND.

Read More

Dr. Head quoted in Alzforum about cerebrovascular disease in Down syndrome

By Carousel Slider, In the News, UCI MIND

UCI MIND faculty member and professor of pathology, Elizabeth Head, PhD, is quoted in last week’s Alzforum article about Alzheimer’s disease immunotherapies and the high rates of cerebrovascular pathology in people with Down syndrome.   To read the story, visit Alzforum from August 25th.

The post Dr. Head quoted in Alzforum about cerebrovascular disease in Down syndrome appeared first on UCI MIND.

Read More

The Link Between Air Quality and Your Longevity

By Carousel Slider, In the News, UCI MIND

Smoggy air can hurt your health even after the smoke has cleared. But you can lower your risk. Some animal research suggests that fine particles can make their way into the brain, says Masashi Kitazawa, an associate professor of environmental and occupational health at the University of California, Irvine. He recently co-wrote a study that found that older mice who were exposed to polluted air were at an increased risk of developing Alzheimer’s disease than those who got purified air. Even the younger mice who were exposed to polluted air had some memory loss and cognitive decline, he says. “As long…

The post The Link Between Air Quality and Your Longevity appeared first on UCI MIND.

Read More

UC Irvine is part of $16 million effort to increase dementia research representation

By Carousel Slider, In the News, UCI MIND

More Asian Americans, Native Hawaiians and Pacific Islanders sought for studies on aging August 2, 2023—With a $16 million grant from the National Institute on Aging, the University of California, San Francisco and the University of California, Irvine will work with community partners to improve the representation of Asian American, Native Hawaiian and Pacific Islander adults in research on aging, caregiving, and Alzheimer’s disease and related dementias. The new project builds on a previous effort by academic leaders and a large variety of community-based organizations with strong ties to the AANHPI population. The Collaborative Approach for AANHPI Research and Education successfully established…

The post UC Irvine is part of $16 million effort to increase dementia research representation appeared first on UCI MIND.

Read More

Direct to Consumer Blood Tests for Alzheimer’s disease

By Carousel Slider, In the News, UCI MIND

Quest Diagnostics recently announced the launch of a direct-to-consumer blood test to detect amyloid plaques in the brain. The test examines the ratio of Ab42/Ab40 in the plasma. Based on the Quest website, the test results are provided in numeric fashion, as well as based on categories of low, intermediate, and high risk of amyloid presence in the brain (with lower numbers on the plasma Ab ratio associated with higher likelihood of amyloid being present in the brain). As can be seen on the website, there is a high degree of overlap on test results among those with elevated compared…

The post Direct to Consumer Blood Tests for Alzheimer’s disease appeared first on UCI MIND.

Read More

Insight: Promising new Alzheimer’s drugs may benefit whites more than Blacks

By Carousel Slider, In the News, UCI MIND

Groundbreaking treatments for Alzheimer’s disease that work by removing a toxic protein called beta amyloid from the brain may benefit whites more than Black Americans, whose disease may be driven by other factors, leading Alzheimer’s experts told Reuters. The two drugs – Leqembi, from partner biotech firms Eisai (4523.T) and Biogen (BIIB.O), and an experimental treatment developed by Eli Lilly (LLY.N), donanemab – are the first to offer real hope of slowing the fatal disease for the 6.5 million Americans living with Alzheimer’s. Although older Black Americans have twice the rate of dementia as whites, they were screened out of clinical trials of these…

The post Insight: Promising new Alzheimer’s drugs may benefit whites more than Blacks appeared first on UCI MIND.

Read More

UC Irvine receives record $653 million in research funding for fiscal 2022-23

By Carousel Slider, In the News, UCI MIND

From cutting-edge research on Alzheimer’s disease to an innovative effort to include environmental justice and community engagement in climate and sustainability science research and education, University of California, Irvine scholars, scientists and physicians are blazing new paths to help change the world. And their impact keeps growing. In fiscal 2022-23, which ended June 30, UCI received the most research funding in campus history: $653 million in grants and contracts. Awards from federal and state agencies, leading foundations and forward-thinking companies rose by 12.7 percent over the 2021-22 total of $580 million, reflecting strong support for UCI’s top-ranked faculty, first-rate facilities,…

The post UC Irvine receives record $653 million in research funding for fiscal 2022-23 appeared first on UCI MIND.

Read More

Full A4 results presented at AAIC

By Carousel Slider, In the News, UCI MIND

Results were presented on Monday from the first-of-its kind Anti-Amyloid treatment in Asymptomatic Alzheimer’s (A4) Study. The A4 was a more than 10-year project to conduct one of the first and largest “preclinical” Alzheimer’s disease clinical trials, testing a compound for potential disease-slowing properties before memory problems begin in a population deemed at risk based on an amyloid PET scan biomarker test. Unfortunately, the drug studied, solanezumab, did not slow memory worsening compared to placebo in this trial. This was surprising given the previous findings in which solanezumab had appeared to have very small but seemingly real effects in symptomatic…

The post Full A4 results presented at AAIC appeared first on UCI MIND.

Read More

Full Donanemab results presented at AAIC

By Carousel Slider, In the News, UCI MIND

Results were presented on Monday for TRAILBLAZER-ALZ-2, a registration trial of the monoclonal antibody donanemab, which was previously announced as positive. The data were highly convincing that donanemab has a significant effect of slowing disease progression in Alzheimer’s disease and almost certainly points to a full clinical approval for the drug by the FDA in the future. The primary analytic group under study in this TRAILBLAZER study (there are several different clinical trials of donanemab sponsored by Eil Lilly under the moniker of “TRAILBLAZER”) was patients with “low-to-medium tau burden,” assessed with a tau PET scan. Unlike the previous trial…

The post Full Donanemab results presented at AAIC appeared first on UCI MIND.

Read More

Do reading, puzzles, and similar activities really stave off dementia?

By Carousel Slider, In the News, UCI MIND

MNT spoke with Dr. Karen D. Lincoln, a professor in the Department of Environmental and Occupational Health at the University of California, Irvine. She noted that while some evidence suggests that cognitive exercises like crossword puzzles or word games slow cognitive decline in those with mild cognitive impairment, the evidence is inconclusive. … “[I]f you like to play dominoes, spades, or bid whist, you are actually engaging in healthy brain exercises,” she said. “Not necessarily because the games are very challenging and require good memory, but because the game is played with others. Social engagement is good for the brain!” Read…

The post Do reading, puzzles, and similar activities really stave off dementia? appeared first on UCI MIND.

Read More
English